Senti Biosciences (SNTI) Equity Average (2021 - 2025)
Senti Biosciences (SNTI) has 5 years of Equity Average data on record, last reported at $16.4 million in Q3 2025.
- For Q3 2025, Equity Average fell 45.51% year-over-year to $16.4 million; the TTM value through Sep 2025 reached $16.4 million, down 45.51%, while the annual FY2024 figure was $46.3 million, 52.33% down from the prior year.
- Equity Average reached $16.4 million in Q3 2025 per SNTI's latest filing, down from $31.3 million in the prior quarter.
- Across five years, Equity Average topped out at $147.3 million in Q3 2022 and bottomed at -$116.6 million in Q1 2022.
- Average Equity Average over 5 years is $29.2 million, with a median of $31.5 million recorded in 2025.
- Peak YoY movement for Equity Average: skyrocketed 546.22% in 2023, then plummeted 72.21% in 2024.
- A 5-year view of Equity Average shows it stood at -$106.4 million in 2021, then skyrocketed by 225.74% to $133.8 million in 2022, then crashed by 44.0% to $74.9 million in 2023, then tumbled by 72.21% to $20.8 million in 2024, then fell by 21.3% to $16.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $16.4 million in Q3 2025, $31.3 million in Q2 2025, and $31.8 million in Q1 2025.